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Abstract
Malaria, one of the most problematic infectious diseases worldwide, is on the rise. The absence of an
eﬀective vaccine and the spread of drug-resistant strains of Plasmodium clearly indicate the necessity for the
development of new chemotherapeutic agents and the identiﬁcation of novel targets. The recent discovery
of a relict, non-photosynthetic plastid-like organelle, the so-called apicoplast, in Plasmodium has opened up
new avenues in malaria research. It also initiated the Plasmodium falciparum genome sequencing project,
which revealed a number of biochemical pathways previously unknown to Plasmodium, i.e. cytosolic
shikimate pathway, apicoplastic type II fatty acid, non-mevalonate isoprene and haem biosyntheses. Since
these vital biosynthetic processes are absent in humans or fundamentally diﬀerent from those found in
humans, they represent excellent targets for pharmaceutical interventions. We are interested in the type II
fatty acid synthase (FAS II) system of malaria parasite and focus on the FabI enzyme, the only known
enoyl-ACP reductase in Plasmodium involved in the ﬁnal reduction step of the fatty acid chain elongation
cycle. Here we describe the general aspects of fatty acid biosynthesis, its essentiality to the malaria parasite
and our continuing eﬀorts to discover in Turkish medicinal plants natural antimalarial agents, which
speciﬁcally target the plasmodial FabI enzyme.
Introduction
Malaria is a mosquito-borne disease transmitted
by inoculation of the host with the Plasmodium
parasite. Plasmodium is a single-celled protozoan
belonging to the phylum Apicomplexa, which is
known for possessing an apical complex facilitat-
ing the invasion of host cells. Although there are
over 100 identiﬁed Plasmodium species, only four
of these parasites (P. falciparum, P. vivax, P. ovale
and P. malariae) cause human malaria, with
P. falciparum being the most lethal. Malaria is an
ancient disease and despite all eﬀorts, has
remained one of the major threats to public health
and economic development worldwide. Approxi-
mately 40% of world population lives in areas
where malaria is transmitted, which means
2.5 billion people in 90 countries. Malaria ranks
with other infectious diseases, such as tuberculosis
and AIDS, and infects 300–500 million people
annually, of which over 1 million people, espe-
cially children under 5 years of age, die (WHO,
2000). For decades, malaria chemotherapy has
relied on a limited number of drugs with severe
side eﬀects. The spread of resistance to these drugs
caused a recent malaria burden underlining the
urgent need for new antimalarial drugs and novel
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biological targets. Among the many exciting new
targets revealed by the P. falciparum genome
sequencing project are the enzymes of the api-
coplast.
Discovery of apicoplast
Although microscopists had observed an unknown
organelle in Plasmodium in the 1970s (Kilejian,
1975), the discovery of apicoplast occurred only in
the mid-1990s (McFadden et al., 1996). This un-
ique, apically positioned organelle owes its dis-
covery to its 35-kb genome, which was investigated
by immunogold labelling and in situ hybridization
experiments (Waller et al., 1998; Surolia et al.,
2004). By using bioinformatics and the metabolic
pathways of plant chloroplasts and bacteria as
models, an extensive network for apicoplast
functions has recently been reconstructed (Ralph
et al., 2004). There have been long debates over
the origin of apicoplast, but recent evidence sug-
gests that apicoplast, as all other plastids, arose
from cyanobacterium (McFadden and Roos, 1999;
Williams and Keeling, 2003). The origin of api-
coplast from cyanobacterium through a secondary
endosymbiosis process is illustrated in Figure 1.
The photosynthetic cyanobacterium (prokaryote)
is engulfed by a primary eukaryote (red or green
alga), a process referred to as primary endosym-
biosis. This cyanobacterium is the ancestor of all
plastids, the so-called primary plastids, found in
red–green algae and land plants (McFadden,
2001). In secondary endosymbiosis, this primary
plastid-containing alga is engulfed and retained by
a second heterotrophic eukaryote, i.e. Plasmodium.
Due to the two subsequent endosymbiotic events,
the apicoplast is surrounded by four membranes,
instead of the two found in primary plastids.
During both primary and secondary endosymbi-
osis processes, which are over millions of years of
evolutionary or adaptation processes, the endo-
symbiont and host were integrated in a process
involving many gene losses and gene transfers. As
a result of the former, the secondary plastid (api-
coplast) became non-photosynthetic, and this was
probably no longer required in the new environ-
ment. Besides gene losses, there have been also
signiﬁcant gene transfers from the endosymbiont
to the new host nucleus, reducing the apicoplast
genome to a bare minimum (McFadden, 2001).
Although the apicoplast genome expresses a small
number of genes and has some housekeeping
processes (e.g. replication, transcription, transla-
tion), the majority of apicoplast proteins are
encoded by genes in the nuclear genome of the
Figure 1. The origin of apicoplast. The photosynthetic cyanobacterium (the small organism) is engulfed (A) by a heterotrophic
eukaryote (red or green alga), and retained (B). During this process, referred to as primary endosymbiosis, some of the genes from
the primary endosymbiont are transferred to the host (alga) nucleus. Subsequently, this alga containing the endosymbiont (= pri-
mary plastid) is engulfed (C) and retained (D) by a second heterotrophic eukaryote, Plasmodium. This process (secondary endosym-
biosis) involved the loss of many genes, by which the plastid became non-photosynthetic, and signiﬁcant gene transfers to the new
host nucleus, which reduced the apicoplast genome enormously (E). The 35-kb circular genome of apicoplast expresses a small num-
ber of genes, but relies on nuclear genes to provide the necessary enzymes that operate in several vital anabolic processes, i.e. fatty
acid biosynthesis. A specialized transport system delivers these proteins (enzymes) to the organelle across four membranes.
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host. The products of these genes (proteins) are
post-translationally targeted to the apicoplast
organelle via the secretory pathway, courtesy of a
bipartite N-terminal leader sequence (Waller et al.,
1998; McFadden and Roos, 1999). It is estimated
that 500 proteins are exported to the apicoplast
(Coppel et al., 2004; Ralph et al., 2004), making
up approximately 15% of the whole P. falciparum
genome (Chaudhary and Roos, 2005). If the obli-
gate intracellular Apicomplexan parasites as well
as the apicoplast are obviously non-photosyn-
thetic, why have they kept this organelle for mil-
lions of years? The answer to this puzzle could be
given soon: Apicoplast is not only interesting from
an evolutionary perspective, but is indispensable
for the malaria parasite as it is the site of several
vital anabolic processes. The ﬁrst-identiﬁed and
probably best understood function of the apicop-
last is the type II fatty acid biosynthesis (Waller
et al., 1998), followed by the non-mevalonate
isoprene (DOXP/MEP) pathway (Jomaa et al.,
1999) and partly haem biosynthesis (Sato et al.,
2000). A comprehensive anabolic map of the api-
coplast functions has been reported recently by
Ralph et al. (2004). The Plasmodium genome
sequencing project has uncovered another critical
biochemical process, the shikimate pathway, in
Plasmodium (Roberts et al., 1998). Although this
pathway was originally thought to take place in
the apicoplast, recent studies localized it to the
cytosol of Plasmodium (Fitzpatrick et al., 2001).
Fortunately, all these core anabolic pathways are
prokaryotic in nature and are either absent in
humans or are fundamentally diﬀerent from those
found in humans. These prokaryotic anabolic
pathways, together with prokaryotic type house-
keeping functions on which the malaria parasite
depends, are excellent targets for pharmaceutical
interventions (Figure 2). Indeed, apicoplast DNA
replication, transcription, translation, fatty acid
and isoprenoid biosynthesis have been all vali-
dated as drug targets (for excellent reviews, see
Ralph et al., 2001, 2004; Wiesner and Seeber,
2005). This review, however, will only cover the
plasmodial type II fatty acid biosynthesis (FAS) as
a biological target for antimalarial drug discovery.
Organization and the importance of the type II
FAS to Plasmodium
The fundamental process of fatty acid biosyn-
thesis is highly conserved, and involves four basic
reactions; a condensation, a reduction, a dehy-
dration, and another reduction (Figure 3). The
fatty acid synthase (FAS) is the principal enzy-
matic unit of this process. Although the basic
process is conserved, there are still major diﬀer-
ences in the organization of fat biosynthesis
among diﬀerent organisms and based on the
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Figure 2. Basic metabolism and drug targets in Plasmodium.
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enzymes involves, two distinc biosynthetic path-
ways can be recognized: Higher eukaryotes
(including human), fungi and some mycobacteria
synthesize fatty acids by a large multifunctional
enzyme in which each reaction is catalyzed by a
discrete domain within a single cytosolic poly-
peptide, the so-called type I FAS. The type II
fatty acid system is widespread among bacteria
and is restricted in eukaryotes to the chloroplasts
of the plants and the algae. In contrast to the
type I, each individual enzymatic reaction is
carried out by a separate, distinct enzyme
encoded by unique genes. As will be discussed
below, the type II pathway was recently identiﬁed
in several Apicomplexan parasites, including P.
falciparum, Toxoplasma gondii (Waller et al.,
1998) and Trypanosoma brucei (Morita et al.,
2000; Berriman et al., 2005).
As a central component of most lipids, fatty
acid biosynthesis is critical for all living organ-
isms. In addition to being the major component
of cell membranes, fatty acid lipids represent an
important form of energy. They also play a key
role in a variety of speciﬁc biological processes,
e.g. signal transduction and protein acylation. Fat
biosynthesis is also essential to the cell growth,
diﬀerentiation and homeostasis of Plasmodium.
Lipid metabolism is dramatically elevated during
the erythrocytic phases, in which the parasite
grows and divides enormously fast. Fatty acids
are demanded not only for energy and nutrient
acquisition and maturation, but also for the
membrane biogenesis of the new daughter cells.
On the other hand, when Plasmodium invades
human cells, it has to secure its environment by
forming a parasite-made compartment, the
so-called parasitophorous vacuole (Vial et al.,
2003). The membrane of this vacuole also pro-
tects the parasite against the immune system of
the host. Recent studies suggest that Plasmodium
needs its own fatty acids in order to form and
expand the vacuole membrane (Sinnis and Sim,
1997). However, it had long been believed that
the malaria parasite is unable to make its own
fatty acids do novo, instead, being completely
dependent on scavenged fatty acids from the host
erythrocyte and serum. This view has been over-
turned with the discovery of apicoplast in 1996,
followed by the identiﬁcation of the very ﬁrst
nucleus-encoded genes for plastid-localized
enzymes, such as FabB, FabF, FabH and FabI
(Waller et al., 1998). This was the ﬁrst indication
of the presence of a type II FAS pathway in
Plasmodium. In 2002, when the Plasmodium gen-
ome project was ﬁnished (Gardner et al., 2002),
no cytosolic FAS genes or type I FAS complexes
were found anywhere in the entire genome. In
labelling experiments, P. falciparum incorporated
both acetate and malonyl-CoA into fatty acids in
vivo and in vitro (Surolia and Surolia, 2001). All
these data suggest that Plasmodium is able to
synthesize fatty acids through a type II pathway
and that this process is restricted to the apicop-
last.
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Figure 3. Type II fatty acid biosynthesis and its enzymes. ACC: acetyl-CoA carboxylase, ACP: acyl carrier protein, FabD: ACP
transacylase, FabH:b-ketoacyl-ACP synthase III, FabG:b-ketoacyl-ACP reductase, FabA:b-hydroxydecanoyl-ACP dehydratase/
isomerase, FabZ:b-hydroxyacyl-ACP dehydratase FabI: enoyl-ACP reductase, FabB:b-ketoacyl-ACP synthase I, FabF:b-ketoacyl-
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The enzymes and the inhibitors of type II FAS
Acetyl-CoA is the major fatty acid precursor. The
impermeability of the apicoplast membrane to
acetyl-CoA has generated many discussions over
the origin of the acetyl-CoA in Plasmodium. After
much debate, it has now been established that the
acetyl-CoA needed for FAS is generated from
pyruvate by the plastidic pyruvate dehydrogenase
complex (Foth et al., 2005). The ﬁrst enzyme of the
fatty acid biosynthesis is acetyl-CoA carboxylase
(ACC), which carboxylates acetyl-CoA to yield
malonyl-CoA. Malonyl-CoA is then transferred to
the acyl carrier protein (ACP) by the FabD (ACP
transacylase) enzyme. ACP is the small, highly
acidic acyl carrier protein that shuttles the hydro-
phobic fatty acyl intermediates from enzyme to
enzyme (as thioester). The cycles of the fatty acid
elongation are initiated by the condensation of
malonyl-ACP with acetyl-CoA catalyzed by the
FabH enzyme (b-ketoacyl-ACP synthase III). The
second step in the elongation cycle is the NADPH-
dependent reduction of b-ketoacyl-ACP to b-hy-
droxylacyl-ACP. This reaction is carried out by
FabG (b-ketoacyl-ACP reductase) protein. Next,
water is removed by Fab A (b-hydroxydecanoyl-
ACP dehydratase/isomerase) and/or FabZ (b-hy-
droxyacyl-ACP dehydratase) to form trans-2
-enoyl-ACP. The ﬁnal step in the elongation process
is the NADH-dependent reduction of the double
bond. This key step is catalyzed by FabI, the only
enoyl-ACP reductase (ENR) enzyme in Plasmo-
dium. Subsequent cycles are started by the conden-
sation of malonyl-ACP, a two carbon atoms donor,
with acyl-ACP by either FabB (b-ketoacyl-ACP
synthase I) or FabF (b-ketoacyl-ACP synthase II).
The cycles continue until a certain length of fatty
acid chain is achieved. In Plasmodium, decanoic
(C-10), lauric (C-12) and myristic (C-14) acids are
the major products of the FAS process (Vial et al.,
2003), whereas palmitic acid (C-16) is the most
predominant fatty acid synthesized in humans.
In conclusion, each step of the type II FAS is
catalyzed by certain speciﬁc enzyme(s) and each
enzyme in this process is targetable, giving multi-
ple opportunities for interventions. Since the FAS
II system is absent in humans, FAS II provides a
great opportunity for therapeutic applications.
Indeed, the type II fatty acid synthesis has been
validated repeatedly as an eﬀective antimicrobial
target. Some of the inhibitors are shown in
Figure 4. The fungal metabolite thiolactomycin
interferes with the condensing enzymes (FabB,
FabF and FabH) of the bacterial FAS system.
This compound is only weakly active against
P. falciparum (IC50 50lM), and the sensitivity of
thiolactomycin to the condensing enzymes of
Plasmodium is on the order of FabF>FabB‡-
FabH (Surolia et al., 2004). The second natural
product known to block the fatty acid biosynthesis
of bacteria is cerulenin, also of fungal origin. The
major target of cerulenin, is FabB, and FabF is
less sensitive. Cerulenin inhibits growth of P. fal-
ciparum in human erytrocytes (IC50 10–20 lM)
(Surolia and Surolia, 2001; Waller et al., 2003).
The other three compounds, isoniazid,
diazaborines and triclosan target FabI, the key
regulatory and rate-limiting enzyme of the type II
FAS. Isoniazid is the ﬁrst line drug used to treat
tuberculosis. Although it has been used in clinics
for more than 50 years, its mechanism of action
remained unknown until mid-90s, where it was
shown to inhibit the InhA enzyme, the FabI ana-
log of M. tuberculosis (Parikh et al., 2000).
Diazaborines are broad-spectrum antimicrobiot-
ics, but due to boron, they are highly toxic in vivo.
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Figure 4. The best known inhibitors of the type II fatty acid biosynthesis.
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Isoniazid and diazaborines are covalent inhibitors
of FabI (Heat et al., 2002). In contrast, the chlo-
rinated bis-phenol, triclosan, binds the bacterial
FabI enzyme noncovalently (by hydrogen bonds)
and forms a ternary complex with the enzyme and
NAD+ (Surolia and Surolia, 2001; Perozzo et al.,
2002). By removing the FabI protein from the
catalytic cycle, triclosan rapidly inhibits the fat
biosynthesis. Triclosan is a very potent, broad-
spectrum synthetic biocide and is widely used in
household formulations, toiletries, toothpastes,
lotions etc. as antibacterial agent.
The FabI enzyme
Over the last 5 years, several groups have cloned
and sequenced the fabI gene. The FabI protein
(PfFabI) encoded by this gene was also puriﬁed
(McLeod et al., 2001; Surolia and Surolia, 2001;
Perozzo et al., 2002) and its aminoacid sequence
was compared with the FabI enzymes of plants
(Brassica napus), and of bacteria (E. coli and
M. tuberculosis). Surprisingly, the plasmodial
FabI enzyme had a much greater sequence simi-
larity with the plant enzyme than with the ENRs
of bacterial origin, which indicates the ‘plant
connection’ in malaria parasites.
Above-mentioned groups also found out that
triclosan, a potent inhibitor of bacterial FabI,
inhibits the plasmodial FabI enzyme (PfFabI) in a
very similar fashion and with similar potency. In
our studies, its enzyme inhibitory concentration
(IC50 value) was about 14 ng/ml (50 nM). Triclo-
san inhibits the growth of P. falciparum in vitro
and is also active in vivo in the P. berghei mouse
model (rodent malaria) without any signiﬁcant
toxicity (Surolia and Surolia, 2001). All these re-
sults indicate that the FabI enzyme is a realistic
target for antimalarial chemotherapy.
The application of FabI-target-based antimalarial
screening in activity-guided natural product
isolation procedures
The discovery that P. falciparum used a type II
FAS system for fatty acid biosynthesis has opened
the door for developing antimalarial drugs that are
speciﬁc to this pathway. All of the evidence pre-
sented above encouraged us to search for
antimalarial natural compounds, which selectively
inhibit the fatty acid pathway of P. falciparum. As
previously mentioned, there are only two natural
products, thiolactomycin and cerulenin, both
fungal metabolites, which have been demonstrated
to interfere with the individual enzymes in the type
II FAS system of the malaria parasite. However,
as they target the condensing enzymes (FabB,
FabF, and FabH), no natural product has been
reported so far which has FabI inhibitory activity.
Because the active site of the enzyme is known and
the crystal structure is available in the literature
(McLeod et al., 2001; Perozzo et al., 2002), FabI
was chosen as a primary target for our further
studies. Triclosan is so far the most potent inhib-
itor of PfFabI, however, a study reports that it
inhibits enoyl reductase of type I fatty acid syn-
thase (Liu et al., 2002). On the other hand, the
amino acid sequence of PfFabI has a greater
similarity with the plant FabI than with that of
E. coli (EcFabI) (Perozzo et al., 2002), which led
us to hypothesize that plants might provide more
potent PfFabI inhibitors than triclosan.
We employed a triple screening strategy in our
activity guided isolation protocol, i.e., every step
of the isolation process, from extraction to the
solvent-solvent partition, from fractionation to the
puriﬁcation, was monitored by three diﬀerent
aspects of bioactivity to obtain the active princi-
ple(s):
1. First, we determined the in vitro antiplasmo-
dial activity of the crude plant extracts, as well
as the fractions and the pure compounds
isolated therefrom, on bloodstage forms of the
multidrug-resistant K1 strain of P. falciparum.
The method used is a standard one that mea-
sures the incorporation of radiolabelled 3H-
hypoxanthine, which is taken up by the para-
site for purine salvage and DNA synthesis, as
an indication of parasitic growth (Sperandeo
and Brun, 2003).
2. The same plant samples were tested simulta-
neously for enzyme inhibitory activity on the
recombinant FabI of P. falciparum (PfFabI),
in order to see if the antiplasmodial activity is
due to FabI inhibition. The enzyme was heter-
ologously expressed in E. coli and puriﬁed as
described previously (Perozzo et al., 2002). The
method we employ is a well-known in vitro
spectrophotometric assay whose details have
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been reported (Tasdemir et al., 2005a, b).
Brieﬂy, the enzyme assay (Figure 5) uses croto-
nyl-CoA as the substrate and in the presence of
NADH, FabI reduces the double bond to yield
butyrylCOA. The consumption of the cofactor
NADH (to NAD+) is reﬂected as an absorp-
tion decrease at 340 nm. In the presence of a
speciﬁc FabI inhibitor, the oxidation of
NADH to NAD+ will be prevented. The reac-
tion mixture is read spectrophotometrically for
1 min. and the IC50 values are estimated from
graphically plotted dose-response curves. Tri-
closan was used as a positive control.
3. In addition to the antiplasmodial and PfFabI
enzyme inhibiting activities, the cytotoxic
potential of the same plant materials on mam-
malian L6 cells were determined. This enables
us to assess the antiparasitic selectivity of the
plant-based research material. An eﬀective
drug should not possess cytotoxicity on mam-
malian cells.
To our knowledge, this is the ﬁrst type II FAS-
target-based antimalarial screening approach
employed in the ﬁeld of natural product research.
Discovery of antimalarial natural products
targeting the plasmodial FabI enzyme
Using the above-mentioned strategy, we have been
screening crude extracts obtained from Turkish
medicinal plants, especially the endemic ones. Two
such projects have recently been completed. The
ﬁrst project investigated the ethanolic root extract
of the endemic Scrophularia lepidota (Scrophular-
iacea), on which no chemical or biological study
had previously been conducted. In preliminary
screenings, the crude extract showed activity
against the multidrug-resistant (K1) strain of
P. falciparum (IC50 17.5 lg/ml) and moderately
inhibited the puriﬁed P. falciparum FabI enzyme
(IC50 80 lg/ml) without any sign of toxicity on L6
cells (IC50 > 90 lg/ml). By employing a combina-
tion of reversed phase (C18) VLC (Vacuum Liquid
Chromatography), MPLC (Medium Pressure Li-
quid Chromatography) and normal phase (SiO2)
CC (Column Chromatography), we have isolated
eleven compounds, two of which were new
(Tasdemir et al., 2005a). During the puriﬁcation
process, we have observed diminishing bioactivity.
This is a well-known phenomenon in activity-di-
rected natural product isolation and might be due to
decomposition of the (unstable) natural products
during the chromatographic processes. The other
possibility is that the initial bioactivity is a result of
the synergistic eﬀect of several plant constituents,
which show less activity in the pure form. Hence,
despite the promising antiplasmodial potential of
the crude extract of S. lepidota, the pure compounds
isolated therefromwere either completely inactive or
not as active as expected. Interestingly, only the
minor iridoid-related aglycone, ())-ningpogenin
(Figure 6), was found to have some antiplasmodial
(IC50 40.6 lg/ml) and enzyme inhibitory potential
(IC50 100 lg/ml). This compound possessed no
cytotoxicity against mammalian cells (IC50 > 90lg/
ml).We believe that subsequent medicinal chemistry
might lead to the optimization of the inhibitory
activity of ())-ningpogenin.
The second project was carried out on the
aerial parts of another endemic species, Phlomis
brunneogaleata (Lamiaceae). The bioactivity of the
crude MeOH extract was tracked to the H2O-sol-
uble portion, which was separated by a combina-
tion of polyamide, C18 MPLC and silica CC to
elaborate 16 secondary metabolites, two of which
were new (Kırmızıbekmez et al., 2004). Two
common ﬂavonoid glycosides, luteolin 7-O-b-D-
glucopyranoside and its C-3¢-methoxy derivative,
chrysoeriol 7-O-b-D-glucopyranoside, were identi-
ﬁed as antimalarial principles of the crude extract
(IC50 values 2.4 and 5:9 lg/ml, respectively).
Interestingly, luteolin 7-O-glucoside (Figure 6),
but not chrysoeriol 7-O-glucoside displayed good
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enzyme inhibitory potential towards the plasmo-
dial FabI enzyme (IC50 10 lg/ml), which might
indicate the necessity of an ortho-diphenol struc-
ture on ring B for enzyme interaction. The diﬀer-
ence between the in vitro antiplasmodial and
enzyme inhibitory concentrations (IC50s), how-
ever, might suggest that luteolin glucoside has
more than a single target. Fortunately, luteolin
7-O-glucoside displays no toxicity on the mam-
malian L6 cells (IC50 > 90 lg/ml; Kırmızıbekmez
et al., 2004).
Thus, the minor compound ())-ningpogenin
and the common ﬂavonoid glycoside luteolin 7-O-
glucoside appear as the ﬁrst FAS-II inhibiting
natural products that speciﬁcally target the FabI
enzyme of P. falciparum. Although the FabI
inhibitory potential of luteolin 7-O-glucoside is
quite moderate in comparison with triclosan (IC50
FabI 14 ng/ml in our studies), both the antiplas-
modial and enzyme inhibitory capabilities of this
common ﬂavonoid glycoside are comparable and
even better than those of cerulenin and thiolacto-
mycin, the only natural products that inhibit the
FAS of the malaria parasite. Note that the enzyme
targets of the latter fungal compounds are not
FabI, but FabB/FabF and FabH. After discover-
ing that luteolin (Figure 6), the aglycone of lute-
olin 7-O-glucoside with known antimalarial
activity (Chowdhury et al., 2002), exhibits 20-fold
higher enzyme inhibitory activity (D. Tasdemir
et al., unpublished results), we started evaluating a
large ﬂavonoid library for FabI inhibitory poten-
tial in the hope that more potent FabI inhibitors
with signiﬁcant activity in whole cell assays against
P. falciparum would emerge. Concurrently, addi-
tional studies are being made in our laboratory to
understand the mechanism of inhibition and the
binding site of the inhibitors to the enzyme.
As a continuation of the current project, a
further 58 extracts were prepared from various
organs of 16 species of Turkish plants and
screened. Over twenty extracts with signiﬁcant
antimalarial activity were also assessed for their
ability to inhibit the puriﬁed enoyl-ACP reduc-
tase (FabI). Only two Ericaceae plant extracts,
the CHCl3-soluble portion of Rhododendron
ungernii (antiplasmodial activity IC50 3.5 lg/ml)
and the H2O-soluble components of the endemic
Rhododendron smirnovii (antiplasmodial activity
IC50 4.2 lg/ml), strongly inhibited the PfFabI
enzyme with IC50 values of 10 and 0:4 lg/ml,
respectively. The active extracts were fractionated
by Sephadex LH20 or polyamide CC to gain
information about the chemical nature of their
enzyme inhibitory principle(s). The preliminary
data, based on TLC (Thin Layer Chromatogra-
phy) and 1H NMR analyses, indicated that some
(poly)phenolic compounds are responsible for the
antiplasmodial and the FabI inhibition potential
of these extracts (Tasdemir et al., 2005b). The
isolation and characterization of the FabI inhib-
itory principle(s) of these fractions are in progress
in our laboratory.
Conclusions
The completion of both Anopheles mosquito and
Plasmodium genome sequencing projects at almost
the same time opened a new era in malaria
research. Probably the most intriguing aspect to
emerge from the latter project was the discovery of
the apicoplast, a secondary endosymbiotic orga-
nelle derived from an ancient cyanobacterium.
Although the apicoplast is no longer photosyn-
thetic, the parasite is dependent upon this orga-
nelle for other metabolic functions. As a parasite,
Plasmodium is able to absorb many nutrients from
its host, but apparently the compounds synthe-
sized by the apicoplast are either not acquired
from the host at some stage of the life cycle, or
some particular variants need to be synthesized for
specialized purposes (Williams and Keeling, 2003).
Interestingly, the inhibition of apicoplast activities
(e.g. replication) does not usually result in imme-
diate parasite death. This so-called delayed death
phenomenon is well known in Toxoplasma and
was also observed in Plasmodium previously (Divo
et al., 1988). However, inhibitors of Plasmodium
FAS, such as triclosan, thiolactomycin did not
elicit the delayed death response and demonstrated
a rapid parasiticidal eﬀect (Surolia and Surolia,
2001; Surolia et al., 2004). This underlines the
pivotal importance of the fatty acid synthesis for
the survival of the parasite.
Comparative genomic applications have already
proved to be very useful for the identiﬁcation of
substantial divergences between parasites and their
hosts (Chaudhary and Roos, 2005). The signiﬁcant
organizational and structural diﬀerences between
the fatty acid synthesis in themalaria parasite and in
humans make this system an attractive target for
106
malaria drug discovery. FabI is a major point of
regulation for bacterial and plastid fatty acid syn-
thesis and is a common drug target for antibacterial
drug discovery. This enzyme has been shown to be
an excellent target for the development of useful
antiplasmodial agents (Surolia and Surolia, 2001).
Our FabI-target-based antimalarial screening
studies have already yielded the very ﬁrst natural
products, ())-ningpogenin and luteolin 7-O-gluco-
side, with such activity. Although their bioactivities
are moderate, we believe that these compounds
might represent good templates for the development
of stronger PfFabI inhibitors.
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